Date: 2015-10-14
Type of information: Licensing agreement
Compound: two clinical stage fully humanized antibody programs and protein multimerization platform, MULTI-TAG™
Company: Memorial Sloan Kettering Cancer (USA - NY) Y-mAbs Therapeutics (USA - NY)
Therapeutic area: Cancer - Oncology
Type agreement: licensing commercialisation
Action mechanism:
Disease:
Details: * On October 14, 2015, Y-mAbs Therapeutics announced a collaboration with Memorial Sloan Kettering Cancer Center (MSK) through a worldwide exclusive license to commercialize two clinical stage fully humanized antibody programs, and a research collaboration agreement, to further develop protein multimerization platform, MULTI-TAG™. YmAbs is a new biotechnology company focused on novel immunotherapies for cancer. The license from MSK includes anti GD2 and anti B7-H3 antibody programs in clinical development, as well as non-exclusive access to platform technologies to create next-generation humanized, affinity matured bispecific antibodies, the protein multimerization platform, MULTI-TAG™. MSK expects that this collaboration will ensure the commercial development of two large research programs which have evolved at the cancer center in a very unique way. The programs build uponbasic science discoveries made in Dr. Cheung’s MSK laboratory, subsequently supported through philanthropic efforts from many parent-driven initiatives, including substantial awards from theBand of Parents, a specialized non-profit organization dedicated to funding research and new therapies to treat neuroblastoma. These gifts enabled Dr. Cheung to rapidly bring improved antibody drugs into clinical trials to treat children with very few options. Through MSK’s partnership with YmAbs, these promising immunotherapies can now be developed, sustained, and made available to patients worldwide. YmAbs’ initial start-up management team consists of: Thomas Gad, Founder, President and Head of Business Development and Strategy, business entrepreneur, and father of a neuroblastoma survivor; Dr. Claus Møller, MD, PhD, CEO of YmAbs, former Chief Operating Officer, and co-founder of Genmab; Bo Kruse, CFO of YmAbs, and former Chief Financial Officer of Genmab; Torben Lund-Hansen, PhD, SVP, Head of Technical Operations, former SVP, Head of Manufacturing at Genmab.
Financial terms:
Latest news:
